<DOC>
	<DOC>NCT02248155</DOC>
	<brief_summary>The objectives of this Post Marketing Surveillance (PMS) are: - Evaluation of the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Syndrome Scale (IRLS) and Clinical Global Impression Improvement scale (CGI- I) - Evaluation of the time to reaching maintenance dose of pramipexole - Evaluation of work productivity impairment associated with RLS based on the Work Productivity and Activity Impairment Questionnaire (WPAI) questionnaire</brief_summary>
	<brief_title>Observational Study of SifrolÂ® in Patients With Primary Restless Legs Syndrome (RLS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients suffering from primary RLS who are eligible for Pramipexol (PPX) treatment could be included into the study Patients not pretreated with any dopaminergic agent (de novo patients) or patients pretreated with dopaminergic medication Male of female patients of any age The treating physicians are asked to consider the regulations described in the Summary of Product Characteristics (SmPC) for the treatment with pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>